PCM
MYGN icon

Prelude Capital Management’s Myriad Genetics MYGN Stock Holding History

Prelude Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,600
Closed -$191K – 2088
2014
Q1 		$191K Hold
5,600
– – 0.03% 750
2013
Q4 		$117K Buy
+5,600
New +$142K 0.02% 806

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's MYGN Position: Q4 2020 in Review

Prelude Capital Management sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 5,029 shares — an estimated $66K sold.

Prelude Capital Management first reported a position in MYGN in Q3 2013 and held it in 17 quarters. The position peaked at $809K in Q1 2017. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

  • Prelude Capital Management reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
  • Prelude Capital Management sold 5,029 Myriad Genetics shares in Q4 2020, an estimated $66K.
  • Prelude Capital Management first reported a position in Myriad Genetics in Q3 2013 and held it in 17 quarters.
  • Prelude Capital Management's Myriad Genetics position peaked at $809K in Q1 2017.
  • 187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Prelude Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.